Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 5.07 (Submission of Matters to a Vote of Security Holders). 2026 Annual Meeting held June 9, 2026.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- 2026 Annual Meeting held June 9, 2026
- Amended and restated Articles of Incorporation approved by stockholders
- Charter amendment details require review of the accompanying filing exhibit
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Christopher Cain and Tom Frohlich elected Class II directors through 2029
- Cain received 34,373,784 votes for versus 8,041,605 withheld, signaling meaningful shareholder opposition
- PwC ratified as independent auditor for fiscal 2026 with 46,003,217 votes for
- Jury-trial waiver amendment approved with 39,933,495 votes for and 2,481,659 against
- Series A Non-Voting Convertible Preferred Stock holders unanimously approved the jury-trial waiver by written consent
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.